Bofa hikes the Ascendis Prich Price Target to 216 to assert purchase ratings

Ascendis Pharma A/S (NASDAQ:ASND) is According to analysts, one of the best 52-week high stocks to buy. On June 9th, BOFA analyst Tazeen Ahmad repeatedly rated his stock’s “buy” ratings, increasing his price target from $201 to $216.

A biopharmaceutical scientist in a white coat examining a cell microscope.

This adjustment follows the company offering positive interim results from the Phase 2 Coach Trial. This study sought to confirm the efficacy of combined treatments of QW Transcon CNP and QW Transcon HGH in children with chondroplasia (ACH). The study results showed significant annual growth rate benefits for combined treatment.

Analysts say court results are favorable and could strengthen the company’s outlook that once treatment enters the market, it will gain market share. Following the positive test results, Ascendes is expected to release 52 weeks of data from its fourth quarter coach trial.

Similarly, the US Food and Drug Administration (FDA) has accepted the new drug application for Transcon, a candidate drug for the treatment of chondroplasia.

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company that develops and commercializes new therapies for unmet medical needs, particularly in endocrinology and oncology. Leverage our unique Transcon technology platform to create innovative and potentially best in class therapies.

Although we acknowledge ASND’s potential as an investment, we believe certain AI stocks offer greater promotion potential and pose a risk of decline. If you’re looking for a highly undervalued AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report. Best Short-Term AI Stocks.

Read next: 10 Most Popular AI Strains to Avoid Now and Billionaire David E. Shaw’s 10 Small Cap Picks.

Disclosure: None.